A clinical trial to learn how an investigational drug (MP-101) affects on the laboratory signs of the disease when given to Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s Disease (AD) patients

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507195-43-00

Acronym

MP-101-02

Enrollment

Registered

2023-11-28

Start date

2024-07-01

Completion date

Unknown

Last updated

2025-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer’s Disease (AD), Amyotrophic Lateral Sclerosis (ALS)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Hungary

None listed

Source: EU CTIS · Data processed: Feb 4, 2026